3-Hydroxypyrazine-2-Carboxamide CAS 55321-99-8 Purity >98.0% (HPLC) Favipiravir Intermediate COVID-19

Chemical Name: 3-Hydroxypyrazine-2-Carboxamide CAS: 55321-99-8 Appearance: Light Yellow to Brown Powder Purity: >98.0% (HPLC) Intermediate of Favipiravir (CAS: 259793-96-9) in the treatment of Influenza virus infections and COVID-19 High Quality, Commercial Production Inquiry: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminum foil bag, 25kg/Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moistureCommercial Supply Favipiravir and Related Intermediates: Favipiravir CAS 259793-96-9 2-Aminopropanediamide CAS 62009-47-6 Diethyl Aminomalonate Hydrochloride CAS 13433-00-6 3,6-Dichloropyrazine-2-Carbonitrile CAS 356783-16-9 3,6-Difluoropyrazine-2-Carbonitrile CAS 356783-28-3 6-Fluoro-3-Hydroxypyrazine-2-Carbonitrile CAS 356783-31-8 6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS 259793-88-9 3-Hydroxypyrazine-2-Carboxamide CAS 55321-99-8
Item Specifications
Appearance Light Yellow to Brown Powder
Identification IR, HPLC
Loss on Drying <1.00%
Single Impurity <0.50%
Heavy Metals ≤20ppm
Purity >98.0% (HPLC)
Test Standard Enterprise Standard
Usage Intermediate of Favipiravir (CAS 259793-96-9)

Description:

Specifications:

Package & Storage:

Chemical Name 3-Hydroxypyrazine-2-Carboxamide
Synonyms T-1105; 3-Hydroxy-2-Pyrazinecarboxamide; Favipiravir Desfluoro Impurity; 3-Oxo-3,4-dihydropyrazine-2-carboxamide
CAS Number 55321-99-8
CAT Number RF-PI295
Stock Status In Stock, Production Scale Up to Kilograms
Molecular Formula C5H5N3O2
Molecular Weight 139.11
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

3-Hydroxypyrazine-2-Carboxamide (CAS 55321-99-8) is the intermediate or impurity of Favipiravir Intermediate (CAS 259793-96-9). Favipiravir is a new broad-spectrum antiviral drug. Favipiravir can be used for antiviral treatment of influenza A and B. Studies have shown that in addition to influenza virus, the drug also exhibits good antiviral activity against a variety of RNA viruses, such as Ebola virus, arena virus, Bunia virus, and rabies virus. During the outbreak of the new Coronavirus Disease 2019 (COVID-19), Favipiravir can be used in the treatment of patients with COVID-19 recommended by WHO. 

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours